TRANSDERM SCOP SUMMARY
The Transderm Scop (transdermal scopolamine) system is a circular flat patch designed for continuous release of scopolamine following application to an area of intact skin on the head, behind the ear. Each system contains 1.5 mg of scopolamine base.
Transderm Scop® is indicated in adults for prevention of nausea and vomiting associated with motion sickness.
[see Clinical Studies]
Post Operative Nausea and Vomiting (PONV)
Transderm Sc?p® is indicated in adults for prevention of nausea and vomiting associated with recovery from anesthesia and/or opiate analgesia and surgery.
[see Clinical Studies]
Media Articles Related to Transderm Scop (Scopolamine Transdermal)
Nausea and Vomiting
Source: MedicineNet Anaphylaxis Specialty [2016.02.22]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 2/22/2016 12:00:00 AM
Giant Bilateral Hemorrhagic Adrenal Myelolipomas
Source: Medscape Radiology Headlines [2016.05.18]
What did CT scan reveal about the cause of this patient's left flank pain associated with nausea and vomiting?
UCLA study finds no evidence linking anti-nausea drug to birth defects
Source: Pregnancy / Obstetrics News From Medical News Today [2016.05.10]
Women suffering from extreme morning sickness often take Zofran (ondansetron) to combat their debilitating nausea and vomiting.
Published Studies Related to Transderm Scop (Scopolamine Transdermal)
Potential of pretreatment neural activity in the visual cortex during emotional
processing to predict treatment response to scopolamine in major depressive
information can predict treatment response to scopolamine in MDD... CONCLUSION: These results implicate cholinergic and visual processing dysfunction
Randomized, double-blind comparison of oral aprepitant alone compared with
aprepitant and transdermal scopolamine for prevention of postoperative nausea and
and vomiting (PONV) treated with oral aprepitant with or without scopolamine... CONCLUSIONS: This trial evaluating the effectiveness of aprepitant alone and in
A comparison of cinnarizine and transdermal scopolamine for the prevention of
seasickness in naval crew: a double-blind, randomized, crossover study. 
reactions... CONCLUSIONS: Higher efficacy, a lower rate of adverse reactions, and convenience
Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. [2011.12]
RATIONALE: Enhancement of histaminergic neurotransmission or histaminergic plus cholinergic neurotransmission may represent novel strategies for improving cognition in Alzheimer's disease. OBJECTIVE: To evaluate the effects of a novel histamine H3 receptor inverse agonist (MK-3134), an acetylcholinesterase inhibitor (donepezil), and their combination in attenuating the cognitive impairment associated with scopolamine... CONCLUSIONS: Exploratory analyses provide evidence for cognitive improvement through inverse agonism of the H3 histamine receptor and for cooperation between human cholinergic and histaminergic neurotransmitter systems. (ClinicalTrials.gov trial registration number: NCT01181310).
Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men. [2011.06]
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Several lines of evidence suggest a possible role of 5-HT(6) receptor antagonists in dementia or cognitive dysfunction of schizophrenia. SB-742457 is a potent 5-HT(6) antagonist and has shown efficacy in different animal models of cognitive impairment. It is currently in development as a cognitive enhancer. Risperidone, commonly used to control agitation and psychotic features in both schizophrenia and Alzheimer's disease, is a D(2)/5-HT(2A ) antagonist with low affinity for 5-HT(6) receptors and limited effects on cognitive parameters. WHAT THIS STUDY ADDS: * As the combination of risperidone and SB-742457 may constitute a reasonable combination in cognitively impaired patients, pharmacodynamic interaction effects were investigated in this study. The only significant drug-drug interaction was a small increase of electroencephalogram (EEG) alpha and beta bands, which might suggest mild arousing activity of SB-742457 on the central nervous system-depressant effects of risperidone. The clinical relevance of these findings in patients remains to be established. Additionally, this study provided an extensive multidimensional pharmacodynamic profile of risperidone in healthy volunteers, showing that this antipsychotic suppresses motor performance (eye-hand coordination, finger tapping and postural stability), alertness, memory and neurophysiological functions (saccadic eye movements and EEG power spectrum). AIM: Several lines of evidence suggest a possible role of 5-HT(6 ) receptor antagonists in cognitive dysfunction of schizophrenia. Atypical antipsychotics, such as risperidone, are currently used in these disorders. Therefore, the pharmacological interactions between the 5-HT(6) antagonist SB-742457 and risperidone were investigated in the light of possible co-medication... CONCLUSION: The pharmacokinetic interactions between SB-742457 and risperidone detected in this study were not clinically relevant. The increase in EEG alpha and beta power is incompatible with enhanced risperidone activity, but could point to mild arousing effects of the combination. Most pharmacodynamic changes of risperidone are consistent with previously reported data. The potential cognitive effects of SB-742457 remain to be established. (c) 2011 Centre for Human Drug Research. British Journal of Clinical Pharmacology (c) 2011 The British Pharmacological Society.
Clinical Trials Related to Transderm Scop (Scopolamine Transdermal)
Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies [Terminated]
Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC) [Active, not recruiting]
A study to evaluate safety and efficacy of topical sirolimus to treat plantar keratoderma in
adults with PC. Subjects may receive either placebo or treatment with at least 1 foot
receiving topical sirolimus at some time. For certain phases of the study treatment
assignment to the right and left foot will be randomized in a double blind fashion. Blood
levels will test systemic absorption of sirolimus. Other safety and efficacy measures will
be taken through the 39-week study duration. Funding Source - FDA OOPD
Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita [Completed]
Pachyonychia congenita (PC) is a rare, autosomal dominant keratin disorder affecting the
nails, skin, oral mucosae, larynx, hair and teeth. Pathogenic mutations in keratin K6a, K6b,
K16 or K17 act via a dominant negative mechanism, leading to manifestations of the disease.
The most disabling PC symptom is a painful plantar blistering and keratoderma that requires
use of ambulation devices in more than 50 percent of patients. Despite our understanding of
the molecular basis of PC, current treatment is limited to mechanical removal of the thick
calluses, non-specific topical keratolytics, and oral retinoids, none of which alleviates
blistering or plantar pain satisfactorily. A public charity, PC Project, has been founded to
support the development of treatments for PC (www. pachyonychia. org). In collaboration with
this charity, a small company, TransDerm, Inc., has developed a small interfering RNA
(siRNA) that specifically targets a mutation in one of the PC keratins, K6a. As this siRNA
targets a single nucleotide mutation, it will only be effective against PC subjects
harboring this specific mutation. There are currently only six known patients who carry this
mutation in the International Pachyonychia Congenita Research Registry, but three of these
patients live in Salt Lake City (a mother and two of her children). We propose to perform a
Phase Ib clinical trial to test the safety and tolerability of TD101 in PC patients carrying
an N171K mutation. We will complete treatment of the adult patient prior to recruitment of
Topical Sirolimus for Plantar Keratoderma in Adults With Pachyonychia Congenita (PC) [Recruiting]
The primary objective of this study is to assess the safety of topical sirolimus (TD201) 1%
for plantar keratoderma for the treatment of pachyonychia congenita. This study would also
like to assess the potential of sirolimus (TD201) to improve the clinical severity of
plantar keratoderma, including pain.
Reports of Suspected Transderm Scop (Scopolamine Transdermal) Side Effects
OFF Label USE (16),
Vision Blurred (8),
Confusional State (6),
Therapeutic Response Unexpected (6),
Inappropriate Schedule of Drug Administration (6),
Withdrawal Syndrome (6), more >>
Page last updated: 2016-05-18